KSQ Therapeutics
What if…
We were able to transform drug discovery into a dramatically more efficient, less expensive, and more precise process?
It turns out…
We can generate uniquely powerful insights into disease biology by leveraging CRISPR-based technologies in new and creative ways.
KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer across multiple drug modalities, including targeted therapies, adoptive cell therapies, and immunotherapies. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo-validated, unbiased target discovery across broad therapeutic areas.
Latest News from KSQ Therapeutics
- KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy 06.12.2024
- MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs 12.04.2019
- KSQ Therapeutics Enhances Board of Directors with Two Appointments 11.12.2019
- KSQ Therapeutics Announces Appointment of Douglas Pagán as Chief Financial Officer 04.16.2019
- KSQ Therapeutics Announces Appointment Of Beni B. Wolf, MD, PhD, As Chief Medical Officer 04.16.2019
- KSQ Therapeutics Secures $80 Million Financing And Advances Broad Pipeline Of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program For PD 1 Resistant Solid Tumors 09.28.2018